ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES HOW INCENTIVES COULD SUPPORT EFFECTIVENESS RESEARCH OF MEDICAL DEVICES

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning on Incentivizing Research Into the Effectiveness of Medical Devices at the Society’s 19th Annual European Congress in Vienna, Austria.  The session was moderated by Rosanna Tarricone, PhD, Professor, Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy. Speakers for the session included:
  • Michael F. Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
  • Mirella Marlow, MBA, MA, Programme Director, Devices and Diagnostics Systems, National Institute for Health and Clinical Excellence (NICE), London, UK
  • Adrian Griffin, MSc, Vice President, HTA and Reimbursement Policy, Johnson & Johnson, High Wycombe, UK
This issue panel examined how incentives could be utilized to increase the range and quality of effectiveness research of medical devices. Speakers noted that medical devices often gain market authorization with significantly less clinical effectiveness evidence than other health technologies, such as pharmaceuticals, because of the different legal requirements for approval of medical devices. The panel also remarked that post-market effectiveness research may actually be more important for medical devices than pharmaceuticals since the performance of the device often depends on the interaction with the user. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×